Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112887 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL2597383 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL9731832 | 0.96 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL6359193 | 0.89 | MTNR1A (0.79) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL9731275 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL53322 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL4101823 | 0.82 | MTNR1A (0.70) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL4101818 | 0.82 | MTNR1A (0.70) | MTNR1AMTNR1BCYP1A2ALOX15MAPT | |
| SCHEMBL1970413 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBDRD2 | |
| SCHEMBL1970411 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | APOTEX INC. (CA) | 2017-10-26 | — | — | US | disclosed |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | APOTEX INC (CA) | 2016-10-13 | — | — | US | disclosed |
| WO-2016044918-A1 | PROCESSES FOR THE PREPARATION OF ROTIGOTINE AND INTERMEDIATES THEREOF | APOTEX INC. (CA) | 2016-03-31 | — | — | WO | disclosed |
| WO-2011146610-A3 | AN ENANTIOSELECTIVE SYNTHESIS OF CHIRAL AMINES FOR THE PRODUCTION OF ROTIGOTINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011146610-A2 | AN ENANTIOSELECTIVE SYNTHESIS OF CHIRAL AMINES FOR THE PRODUCTION OF ROTIGOTINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146610-A2 | AN ENANTIOSELECTIVE SYNTHESIS OF CHIRAL AMINES FOR THE PRODUCTION OF ROTIGOTINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | C1S, C1R, C3AR1 | MTNR1A 556/4885MTNR1B 357/4885CYP1A2 283/4885 |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | ABCB11, EXOC3, C1S | MTNR1A 2409/4885MTNR1B 2775/4885CYP1A2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.